Discussion - Multiple Myeloma

ENG

Majestec-3, CARTITUDE-4

ASH 2025

Strategies and perspectives for r/r MM: Significance of…

H. Einsele, H. Hashmi, B. C. Lipe, M. Merz, F. Schjesvold

ENG

iMMagine--1, inMMyCAR

ASH 2025

Advances in CAR T cell therapy: new constructs,…

H. Einsele, H. Hashmi, B. C. Lipe, M. Merz, F. Schjesvold

ENG

remnant, IFM2021-01 teclille

ASH 2025

Which treatment strategy in NDMM? Is immunotherapy…

H. Einsele, H. Hashmi, B. C. Lipe, M. Merz, F. Schjesvold

Relapsed/Refractory Multiple Myeloma

ENG

CARTITUDE-4

ASH 2025

Is CAR T as good as Dara / Tecli?

Hamza Hashmi, MD

ENG

Majestec-3

ASH 2025

Bispecifics in 2nd-line treatment

Fredrik Schjesvold, MD

ENG

CARTITUDE-4

ASH 2025

Long-term PFS benefit with cilta-cel in RRMM

Brea C. Lipe, MD

ENG

majestec-3

ASH 2025

Tec-Dara as a new Standard in 2nd line

Katja Weisel, MD

ENG

redirectt-1

ASH 2025

Talquetamab + Teclistamab in extramedullary disease

Katja Weisel, MD

ENG

Majestec-3, inMMyCAR

ASH 2025

New gamechanging therapy options

C. Ola Landgren, MD

ENG

Majestec-3

ASH 2025

Majestec-3: the best myeloma abstract at ASH 2025

Maximillian Merz, MD

ENG

redirectt-1

ASH 2025

Talquetamab + Teclistamab meet the unmet need for an…

Hamza Hashmi, MD

ENG

ASH 2025

MMR vaccination in MM patients receiving daratumumab…

Brea C. Lipe, MD

ENG

Majestec-3

ASH 2025

Dara / Tecli - the new SOC for first relapse with MM

Hamza Hashmi, MD

ENG

iMMagine--1

ASH 2025

Anitocel challenges ciltacel

Maximillian Merz, MD

ENG

inMMyCAR

ASH 2025

In vivo CARs are coming

Fredrik Schjesvold, MD

ENG

CARTITUDE-4, Majestec-3, inMMyCAR, iMMagine-1

ASH 2025

Strategies and perspectives for multiple myeloma

Hermann Einsele, MD

ENG

redirectt-1

ASH 2025

Dual targeting for high risk myeloma

Maximillian Merz, MD

ENG

ASH 2025

Still work to do

Brea C. Lipe, MD

Relapsed/Refractory Multiple Myeloma – multi language

GER

Majestec-3

ASH 2025

Majestec-3: Der beste Abstract zum Multiplen Myelom…

Maximillian Merz, MD

NOR

Majestec-3

ASH 2025

Bispesifikke i andrelinje

Fredrik Schjesvold, MD

SWE

Majestec-3, inMMyCAR

ASH 2025

Nya banbrytande behandlingsalternativ

C. Ola Landgren, MD

GER

redirectt-1

ASH 2025

Talquetamab + Teclistamab bei extramedullärer…

Katja Weisel, MD

GER

redirectt-1

ASH 2025

Dual-targeting beim Hochrisiko-Myelom

Maximillian Merz, MD

NOR

inMMyCAR

ASH 2025

In vivo CARs er på vei

Fredrik Schjesvold, MD

GER

majestec-3

ASH 2025

Tec-Dara als neuer Standard in der Zweitlinie

Katja Weisel, MD

GER

iMMagine--1

ASH 2025

Anitocel macht Ciltacel Konkurrenz

Maximillian Merz, MD

GER

CARTITUDE-4, Majestec-3, inMMyCAR, iMMagine-1

ASH 2025

Strategien und Perspektiven beim Multiplen Myelom

Hermann Einsele, MD

Newly Diagnosed Multiple Myeloma

ENG

IFM2021-01 teclille

ASH 2025

Is Dar-Tec better than DRD or DVRD for TIE NDMM?

Hamza Hashmi, MD

ENG

AURIGA

ASH 2025

Importance of DaraLen maintenance after ASCT

Katja Weisel, MD

Newly Diagnosed Multiple Myeloma – multi language

GER

AURIGA

ASH 2025

Bedeutung der DaraLen-Erhaltungstherapie nach ASCT

Katja Weisel, MD

MGUS & Smoldering Myeloma

ENG

GEM-CESAR

ASH 2025

Are we curing SMM?

Brea C. Lipe, MD

Discussion – Chronic/Small Lymphocytic Leukemia

ENG

CLL17, CaDAnCe-101

ASH 2025

Advances in CLL therapy: BTK inhibitors, fixed-duration…

M. Dreyling, T. Eyre

Chronic/Small Lymphocytic Leukemia

ENG

BRUIN CLL-313

ASH 2025

Pirto superior to BR

Martin Dreyling, MD

ENG

CLL17

ASH 2025

Primary results from CLL17

Toby Eyre, MD

ENG

BRUIN LOXO-BTK-18001 BRUIN CLL-321

ASH 2025

Pirtobrutinib as 2L therapy after cBTKi in CLL

Toby Eyre, MD

Chronic/Small Lymphocytic Leukemia – multi language

GER

BRUIN CLL-313

ASH 2025

Pirtobrutinib ist BR signifikant überlegen bei CLL

Martin Dreyling, MD

Discussion – Aggressive Non-Hodgkin-Lymphoma

ENG

R-Pola-Glo, EPCORE DLBCL-3

ASH 2025

Bispecifics and CAR T: are we entering a new era for…

M. Dreyling, M. Jerkeman, S. Ferrero, C. Thieblemont

Aggressive Non-Hodgkin-Lymphoma

ENG

DALY 2-EU

ASH 025

Zamto-cel in r/r DLBCL patients, who are not eligible…

Mats Jerkeman, MD

ENG

ASH 2025

Zanubrutinib and high-dose methotrexate in primary CNS…

Mats Jerkeman, MD

Aggressive Non-Hodgkin-Lymphoma – multi language

SWE

DALY 2-EU

ASH 2025

Zamto-cel för patienter med recidiverande DLBCL, inte…

Mats Jerkeman, MD

SWE

ASH 2025

Zanubrutinib och högdos metotrexat för primärt…

Mats Jerkeman, MD

Discussion – Indolent Non-Hodgkin-Lymphoma

ENG

window-3, TrAVeRse, GLOVe

ASH 2025

Integrating targeted agents and cellular therapy in…

M. Dreyling, T. Eyre, M. Jerkeman, S. Ferrero, C. Sarkozy, C. Thieblemont

ENG

BRUIN, rock-1

ASH 2025

Targeting BTK and BCL-2: where do we go in r/r MCL?

M. Dreyling, T. Eyre, M. Jerkeman, S. Ferrero, C. Sarkozy, C. Thieblemont

ENG

ROSEWOOD, MorningSun, EPCORE FL-1, TRANSCEND FL

ASH 2025

Therapeutic innovations in FL: is cure within reach?…

M. Dreyling, T. Eyre, M. Jerkeman, S. Ferrero, C. Thieblemont, C. Sarkozy

Follicular Lymphoma

ENG

TRANSCEND FL

ASH 2025

3 year clinical update of liso-cel in r/r FL

Simone Ferrero, MD

ENG

EPCORE FL-1

ASH 2025

Outstanding primary results of EPCORE FL-1

Toby Eyre, MD

ENG

MorningSun study

ASH 2025

12 month follow-up of MorningSun for HTB FL - SC…

Simone Ferrero, MD

ENG

EPCORE FL-1

ASH 2025

Epcoritamab + R2 for 2L treatment in r/r follicular…

Mats Jerkeman, MD

ENG

ROSEWOOD

ASH 2025

Final results from phase II trial ROSEWOOD in r/r FL

Simone Ferrero, MD

ENG

EPCORE FL-1

ASH 2025

Primary results of EPCORE FL-1 trial in r/r FL

Simone Ferrero, MD

ENG

epcore FL-1

ASH 2025

E+R² as the new standard for r/r FL

Martin Dreyling, MD

Follicular Lymphoma – multi language

ITA

ROSEWOOD

ASH 2025

Risultati finali del trial di fase II ROSEWOOD per…

Simone Ferrero, MD

ITA

MorningSun study

ASH 2025

Aggiornamento clinico a 12 mesi del trial "MorningSun"…

Simone Ferrero, MD

ITA

EPCORE FL-1

ASH 2025

Risultati preliminari del trial di fase III "EPCORE…

Simone Ferrero, MD

SWE

EPCORE FL-1

ASH 2025

Epcoritamab + R2 som 2:a linjens behandling vid…

Mats Jerkeman, MD

GER

epcore FL-1

ASH 2025

Bispezifischer AK Epcoritamab + R² neuer Standard beim…

Martin Dreyling, MD

ITA

TRANSCEND FL

ASH 2025

Aggiornamento clinico a 3 anni del trial…

Simone Ferrero, MD

Mantle Cell Lymphoma

ENG

ASH 2025

GLOVe: a bispec in 1L for high risk MCL

Clementine Sarkozy, MD, PhD

ENG

ASH 2025

BOVEN is doable für in elderly patients

Clementine Sarkozy, MD, PhD

ENG

TrAVeRse

ASH 2025

TrAVeRse: a triplet as 1L for allcomers!

Clementine Sarkozy, MD, PhD

ENG

TrAVeRse

ASH 2025

AVR, the next step in therapy-evolution of MCL

Martin Dreyling, MD

ENG

ASH 2025

Glofitamab + Len+ Ven in 1L high-risk MCL (GLOVe)

Mats Jerkeman, MD

ENG

window-3

ASH 2025

Window-3: 1L treatment in high risk MCL - effective but…

Clementine Sarkozy, MD, PhD

ENG

BGB-11417-201

ASH 2025

Sonrotoclax monotherpay in R/R MCL

Toby Eyre, MD

ENG

ASH 2025

Boven in older MCL patients

Toby Eyre, MD

Mantle Cell Lymphoma – multi language

FRA

TrAVeRse

ASH 2025

TrAVeRse, une triplette en première ligne d’un LCM pour…

Clementine Sarkozy, MD, PhD

FRA

window-3

ASH 2025

Window-3 chez les sujets de hauts risques en première…

Clementine Sarkozy, MD, PhD

SWE

ASH 2025

Glofitamab + Len+ Ven som primärbehandling vid högrisk…

Mats Jerkeman, MD

GER

TrAVeRse

ASH 2025

AVR nächster Schritt in der Therapieevolution beim MCL

Martin Dreyling, MD

FRA

ASH 2025

GLOVe: un bispécifique en première ligne pour les LCM…

Clementine Sarkozy, MD, PhD

FRA

ASH 2025

BOVEN est faisable chez les sujets âges en première…

Clementine Sarkozy, MD, PhD